Epidemiology of isoniazid resistance mutations and their effect on tuberculosis treatment outcomes

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 8, 2013, Pages 3620-3627

  Huyen, Mai N T ^a   Cobelens, Frank G J ^b   Buu, Tran N ^a   Lan, Nguyen T N ^a   Dung, Nguyen H ^a   Kremer, Kristin ^c,d   Tiemersma, Edine W ^e   Van Soolingen, Dick ^d,f  

^a Pham Ngoc Thach Hospital   (Viet Nam)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^e KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; STREPTOMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; PROMOTER REGION; RURAL AREA; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS; VIET NAM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CATALASE; CODON; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ETHAMBUTOL; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; ISONIAZID; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION; MYCOBACTERIUM TUBERCULOSIS; OXIDOREDUCTASES; PROMOTER REGIONS, GENETIC; RECURRENCE; RIFAMPIN; STREPTOMYCIN; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; VIETNAM; YOUNG ADULT;

EID: 84880322995     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00077-13     Document Type: Article

References (37)

1. World Health Organization. 2012. Global tuberculosis control 2012. World Health Organization, Geneva, Switzerland.
2. Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, Feldman K, Hoffner S, Drobniewski F, Barrera L, van Soolingen D, Boulabhal F, Paramasivan CN, Kam KM, Mitarai S, Nunn P, Raviglione M. 2009. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 373:1861-1873.
3. Menzies D, Benedetti A, Paydar A, Royce S, Madhukar P, Burman W, Vernon A, Lienhardt C. 2009. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med. 6:e1000150. doi:10.1371/journal.pmed. 1000150.
4. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, Baez J, Kochi A, Dye C, Raviglione MC. 2000. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in six countries. JAMA 283:2537-2545.
5. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, Collins D, de Lisle G, Jacobs WR, Jr. 1994. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263:227-230.
6. Musser JM, Kapur V, Williams DL, Kreiswirth BN, van Soolingen D, van Embden JD. 1996. Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and-susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. J. Infect. Dis. 173:196-202.
7. Kelley CL, Rouse DA, Morris SL. 1997. Analysis of ahpC gene mutations in isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 41:2057-2058.
8. Lee AS, Teo AS, Wong SY. 2001. Novel mutations in ndh in isoniazidresistant Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother. 45:2157-2159.
9. Mokrousov I, Narvskaya O, Otten T, Limeschenko E, Steklova L, Vyshnevskiy B. 2002. High prevalence of KatG Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from northwestern Russia, 1996 to 2001. Antimicrob. Agents Chemother. 46:1417-1424.
10. Telenti A, Honore N, Bernasconi C, March J, Ortega A, Heym B, Takiff HE, Cole ST. 1997. Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level. J. Clin. Microbiol. 35:719-723.
11. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME. 2008. Rapid molecular screening for multidrug-resistant tuberculosis in a highvolume public health laboratory in South Africa. Am. J. Respir. Crit. Care Med. 177:787-792.
12. Zhang Y, Heym B, Allen B, Young D, Cole S. 1992. The catalaseperoxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 358:591-593.
13. Ando H, Kondo Y, Suetake T, Toyota E, Kato S, Mori T, Kirikae T. 2010. Identification of katG mutations associated with high-level isoniazid resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 54:1793-1799.
14. Dalla Costa ER, Ribeiro MO, Silva MS, Arnold LS, Rostirolla DC, Cafrune PI, Espinoza RC, Palaci M, Telles MA, Ritacco V, Suffys PN, Lopes ML, Campelo CL, Miranda SS, Kremer K, da Silva PE, Fonseca Lde S, Ho JL, Kritski AL, Rossetti ML. 2009. Correlations of mutations in katG, oxyR-ahpC, and inhA genes and in vitro susceptibility in Mycobacterium tuberculosis clinical strains segregated by spoligotype families from tuberculosis prevalent countries in South America. BMC Microbiol. 9:39. doi:10.1186/1471-2180-9-39.
15. Huyen MN, Tiemersma EW, Lan NT, Cobelens FG, Dung NH, Sy DN, Buu TN, Kremer K, Hang PT, Caws M, O'Brien R, van Soolingen D. 2010. Validation of the GenoTypeMTBDRplus assay for diagnosis of multidrug resistant tuberculosis in South Vietnam. BMC Infect. Dis. 10:149. doi:10.1186/1471-2334-10-149.
16. van Doorn HR, de Haas PE, Kremer K, Vandenbroucke-Grauls CM, Borgdorff MW, van Soolingen D. 2006. Public health impact of isoniazid-resistant Mycobacterium tuberculosis strains with a mutation at aminoacid position 315 of katG: a decade of experience in The Netherlands. Clin. Microbiol. Infect. 12:769-775.
17. Hillemann D, Kubica T, Rusch-Gerdes S, Niemann S. 2005. Disequilibrium in distribution of resistance mutations among Mycobacterium tuberculosis Beijing and non-Beijing strains isolated from patients in Germany. Antimicrob. Agents Chemother. 49:1229-1231.
18. Ghebremichael S, Groenheit R, Pennhag A, Koivula T, Andersson E, Bruchfeld J, Hoffner S, Romanus V, Kallenius G. 2010. Drug resistant Mycobacterium tuberculosis of the Beijing genotype does not spread in Sweden. PLoS One 5:e10893. doi:10.1371/journal.pone.0010893.
19. Anh DD, Borgdorff MW, Van LN, Lan NT, van Gorkom T, Kremer K, van Soolingen D. 2000. Mycobacterium tuberculosis Beijing genotype emerging in Vietnam. Emerg. Infect. Dis. 6:302-305.
20. 2006. Beijing/W genotype Mycobacterium tuberculosis and drug resistance. Emerg. Infect. Dis. 12. 736-743.
21. Buu TN, Huyen MN, Lan NT, Quy HT, Hen NV, Zignol M, Borgdorff MW, Cobelens FG, van Soolingen D. 2009. The Beijing genotype is associated with young age and multidrug-resistant tuberculosis in rural Vietnam. Int. J. Tuberc. Lung Dis. 13:900-906.
22. Burman WJ, Bliven EE, Cowan L, Bozeman L, Nahid P, Diem L, Vernon A. 2009. Relapse associated with active disease caused by Beijing strain of Mycobacterium tuberculosis. Emerg. Infect. Dis. 15:1061-1067.
23. Huyen MN, Buu TN, Tiemersma E, Lan NT, Dung NH, Kremer K, Soolingen DV, Cobelens FG. 2013. Tuberculosis relapse in Vietnam is significantly associated with Mycobacterium tuberculosis Beijing genotype infections. J. Infect. Dis. 207:1516-1524.
24. Hoa NB, Sy DN, Nhung NV, Tiemersma EW, Borgdorff MW, Cobelens FG. 2010. National survey of tuberculosis prevalence in Viet Nam. Bull. World Health Organ. 88:273-280.
25. Huong NT, Lan NT, Cobelens FG, Duong BD, Co NV, Bosman MC, Kim SJ, van Soolingen D, Borgdorff MW. 2006. Antituberculosis drug resistance in the south of Vietnam: prevalence and trends. J. Infect. Dis. 194:1226-1232.
26. Buu TN, Huyen MN, van Soolingen D, Lan NT, Quy HT, Tiemersma EW, Borgdorff MW, Cobelens FG. 2010. The Mycobacterium tuberculosis Beijing genotype does not affect tuberculosis treatment failure in Vietnam. Clin. Infect. Dis. 51:879-886.
27. Huong NT, Duong BD, Co NV, Quy HT, Tung LB, Bosman M, Gebhardt A, Velema JP, Broekmans JF, Borgdorff MW. 2005. Establishment and development of the National Tuberculosis Control Programme in Vietnam. Int. J. Tuberc. Lung Dis. 9:151-156.
28. World Health Organization. 2003. Guidelines for surveillance of drug resistance in tuberculosis,2nd ed. World Health Organization, Geneva, Switzerland.
29. van Soolingen D, de Haas PEW, Kremer K. 2001. Restriction fragment length polymorphism typing of mycobacteria, p 165-203. In Parish T, Stoker NG (ed), In Mycobacterium tuberculosis protocols. Humana Press, Inc, Totowa, NJ.
30. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, Bunschoten A, Molhuizen H, Shaw R, Goyal M, van Embden J. 1997. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J. Clin. Microbiol. 35: 907-914.
31. Supply P, Allix C, Lesjean S, Cardoso-Oelemann M, Rusch-Gerdes S, Willery E, Savine E, de Haas P, van Deutekom H, Roring S, Bifani P, Kurepina N, Kreiswirth B, Sola C, Rastogi N, Vatin V, Gutierrez MC, Fauville M, Niemann S, Skuce R, Kremer K, Locht C, van Soolingen D. 2006. Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J. Clin. Microbiol. 44:4498-4510.
32. World Health Organization. 2009. Treatment of tuberculosis: guidelines, 4th ed. World Health Organization, Geneva, Switzerland.
33. Kremer K, Glynn JR, Lillebaek T, Niemann S, Kurepina NE, Kreiswirth BN, Bifani PJ, van Soolingen D. 2004. Definition of the Beijing/W lineage of Mycobacterium tuberculosis on the basis of genetic markers. J. Clin. Microbiol. 42:4040-4049.
34. Brudey K, Driscoll JR, Rigouts L, Prodinger WM, Gori A, Al-Hajoj SA, Allix C, Aristimuno L, Arora J, Baumanis V, Binder L, Cafrune P, Cataldi A, Cheong S, Diel R, Ellermeier C, Evans JT, Fauville-Dufaux M, Ferdinand S, Garcia de Viedma D, Garzelli C, Gazzola L, Gomes HM, Guttierez MC, Hawkey PM, van Helden PD, Kadival GV, Kreiswirth BN, Kremer K, Kubin M, Kulkarni SP, Liens B, Lillebaek T, Ho ML, Martin C, Mokrousov I, Narvskaia O, Ngeow YF, Naumann L, Niemann S, Parwati I, Rahim Z, Rasolofo-Razanamparany V, Rasolonavalona T, Rossetti ML, Rusch-Gerdes S, Sajduda A, Samper S, Shemyakin IG, Singh UB, Somoskovi A, Skuce RA, van Soolingen D, Streicher EM, Suffys PN, Tortoli E, Tracevska T, Vincent V, Victor TC, Warren RM, Yap SF, Zaman K, Portaels F, Rastogi N, Sola C. 2006. Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics, and epidemiology. BMC Microbiol. 6:23. doi:10.1186/1471-2180-6-23.
35. Tolani MP, D'Souza DT, Mistry NF. 2012. Drug resistance mutations and heteroresistance detected using the GenoType MTBDRplus assay and their implication for treatment outcomes in patients from Mumbai, India. BMC Infect. Dis. 12:9. doi:10.1186/1471-2334-12-9.
36. Farr SB, Kogoma T. 1991. Oxidative stress responses in Escherichia coli and Salmonella typhimurium. Microbiol. Rev. 55:561-585.
37. Buu TN, van Soolingen D, Huyen MN, Lan NT, Quy HT, Tiemersma EW, Kremer K, Borgdorff MW, Cobelens FG. 2012. Increased transmission of Mycobacterium tuberculosis Beijing genotype strains associated with resistance to streptomycin: a population-based study. PLoS One 7:e42323. doi:10.1371/journal. pone.0042323.